Nogales-Gadea Gisela, Garcia-Arumi Elena, Andreu Antonio L, Cervera Carlos, Gamez Josep
Neurology Department, Hospital General. Universitari Vall d'Hebron, Servicio de Neurologia, Passeig Vall d'Hebron 113-135, 08035 Barcelona, Spain.
J Neurol Sci. 2004 Apr 15;219(1-2):1-6. doi: 10.1016/j.jns.2003.10.018.
Allelic heterogeneity and phenotype variability-especially in age at onset, penetrance and progression-are reported in ALS1 families. For this reason, SOD1 gene mutation data in ALS1 patients are currently being gathered to better understand the genotype-phenotype relationship in this disorder. Here, we report the clinical and molecular characteristics of a Spanish ALS1 family with incomplete penetrance.
Clinical data including age at onset, initial topography, progression and survival were available in three affected members. Erythrocyte SOD1 activity was measured in four individuals. Analysis of the SOD1 gene was performed by PCR and direct sequencing.
A novel missense mutation in the exon 5 of the SOD1 gene, an A-to-C transversion at nucleotide position 1485 leading to N139H residue change, was identified in three family members. The phenotype was similar in all cases, with initial symptoms in the distal limb muscles and a mean survival time of around 4 years. Incomplete penetrance was observed in our family, as two obligate carriers did not develop any symptoms of amyotrophic lateral sclerosis (ALS).
N139H is the fifth SOD1 gene mutation reported in Spain, and the first one presenting with incomplete penetrance. Genetic counseling for at-risk relatives in these low-penetrance families could be difficult as some individuals harbouring the mutation remain asymptomatic throughout their lives. Further genetic characterisation of ALS1 families should provide information regarding the distribution of SOD1 mutants in different ethnic groups.
在肌萎缩侧索硬化1型(ALS1)家族中报道了等位基因异质性和表型变异性,尤其是发病年龄、外显率和疾病进展方面。因此,目前正在收集ALS1患者的超氧化物歧化酶1(SOD1)基因突变数据,以更好地了解这种疾病的基因型-表型关系。在此,我们报告一个外显率不完全的西班牙ALS1家族的临床和分子特征。
有3名受影响成员的临床数据,包括发病年龄、首发部位、疾病进展和生存期。对4名个体测定了红细胞SOD1活性。通过聚合酶链反应(PCR)和直接测序对SOD1基因进行分析。
在3名家族成员中鉴定出SOD1基因第5外显子的一个新的错义突变,核苷酸位置1485处的A到C颠换,导致N139H残基改变。所有病例的表型相似,首发症状为肢体远端肌肉受累,平均生存期约4年。在我们的家族中观察到外显率不完全,因为两名必然携带者未出现任何肌萎缩侧索硬化(ALS)症状。
N139H是西班牙报道的第5个SOD1基因突变,也是首个表现出外显率不完全的突变。在这些低外显率家族中,为有风险的亲属提供遗传咨询可能会很困难,因为一些携带该突变的个体终生无症状。对ALS1家族进行进一步的基因特征分析应能提供有关SOD1突变体在不同种族群体中分布的信息。